Modelling cytochromes P450 binding modes to predict P450 inhibition, metabolic stability and isoform selectivity

Drug Discovery Today: Technologies

Volumn 10, Issue 1, 2013, Pages

  Carosati, Emanuele ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; IMIPRAMINE; LIGAND;

BINDING KINETICS; BIOTRANSFORMATION; CATALYSIS; COMPUTATIONAL FLUID DYNAMICS; COMPUTER MODEL; ELECTROPHILICITY; ENANTIOSELECTIVITY; GEOMETRY; HYDROXYLATION; INHIBITION KINETICS; LIVER TOXICITY; METABOLISM; METABOLITE; MOLECULAR DOCKING; MOLECULAR MODEL; MOLECULAR STABILITY; OXIDATION; PROTEIN BINDING; RELIABILITY; REVIEW;

BINDING SITES; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

EID: 84875708476     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.09.007     Document Type: Review

References (42)

1. F.P. Guengerich Cytochrome P450 and chemical toxicity Chem. Res. Toxicol. 21 2008 70 83
2. J. Kirchmair Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms J. Chem. Inf. Model. 52 2012 617 648
3. C.W. Locuson Visible spectra of type II cytochrome P450-drug complexes: evidence that incomplete heme coordination is common Drug Metab. Dispos. 35 2007 614 622
4. S.L.C. Moors Structure-based site of metabolism prediction for cytochrome P450 2D6 J. Med. Chem. 54 2011 6098 6105
5. J. Li IDSite: an accurate approach to predict P450-mediated drug metabolism J. Chem. Theor. Comput. 7 2011 3829 3845
6. P. Vasanthanathan Virtual screening and prediction of site of metabolism for cytochrome P450 1A2 ligands J. Chem. Inf. Model. 49 2009 43 52
7. J. Zaretzki RS-predictor: a new tool for predicting sites of cytochrome P450-mediated metabolism applied to CYP 3A4 J. Chem. Inf. Model. 51 2011 1667 1689
8. P. Rydberg, and L. Olsen Ligand-based site of metabolism prediction for cytochrome P450 2D6 ACS Med. Chem. Lett. 3 2012 69 73
9. G. Cruciani MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist J. Med. Chem. 48 2005 6970 6979
10. M.J. de Groot In silico methods for predicting ligand binding determinants of cytochromes P450 Front. Med. Chem. 3 2006 615 652
11. T. Zhang In silico prediction of cytochrome P450-mediated drug metabolism Comb. Chem. High Throughput Screen. 14 2011 388 395
12. Cruciani G. (2012) Exposure and reactivity optimization to predict sites of metabolism in chemicals. Drug Discov. Today: Technol
13. M.M. Ahlström, and I. Zamora Characterization of type II ligands in CYP2C9 and CYP3A4 J. Med. Chem. 51 2008 1755 1763
14. E. Carosati Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field J. Med. Chem. 47 2004 5114 5125
15. J.P. Jones The effects of nitrogen-heme-iron coordination on substrate affinities for cytochrome P450 2E1 Chem.-Biol. Interact. 193 2011 50 56
16. C.C. Peng Cytochrome P450 2C9 type II binding studies on quinoline-4-carboxamide analogues J. Med. Chem. 51 2008 8000 8011
17. C.C. Peng The effects of type II binding on metabolic stability and binding affinity in cytochrome P450 CYP3A4 Arch. Biochem. Biophys. 497 2010 68 81
18. J. Pearson The kinetic mechanism for cytochrome P450 metabolism of type II binding compounds: evidence supporting direct reduction Arch. Biochem. Biophys. 511 2011 69 79
19. U.P. Dahal Comparative study of the affinity and metabolism of Type I and Type II binding quinoline carboxamide analogues by cytochromes P450 3A4 J. Med. Chem. 55 2012 280 290
20. S. Zhou Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4 Curr. Drug Metab. 5 2004 415 442
21. E. Fontana Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity Curr. Drug Metab. 6 2005 413 454
22. 5) Drug Metab. Dispos. 35 2007 1466 1475
23. A.F. Stepan Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States Chem. Res. Toxicol. 24 2011 1345 1410
24. I. Sushko ToxAlerts: a web server of structural alerts for toxic chemicals and compounds with potential adverse reactions J. Chem. Inf. Model. 52 2012 2310 2316
25. A.S. Kalgutkar Handling reactive metabolite positives in drug discovery: what has retrospective structure-toxicity analyses taught us? Chem. Biol. Interact. 192 2011 46 55
26. S.T.M. Orr Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks J. Med. Chem. 55 2012 4896 4933
27. V. Baty Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal Gastroenterol. Clin. Biol. 18 1994 1129 1131
28. Chembl database; URL: http://www.ebi.ac.uk/chembl
29. Pubchem database; URL: http://pubchem.ncbi.nlm.nih.gov
30. Molecular discovery P450-Consortium page; URL: http://www.moldiscovery. com/consortia/CYP
31. T.I. Oprea Pharmacokinetically based mapping device for chemical space navigation J. Comb. Chem. 4 2002 258 266
32. B. Faller Evolution of the physicochemical properties of marketed drugs: can history foretell the future? Drug Discov. Today 16 2011 976 984
33. P. Crivori Predicting blood-brain barrier permeation from three-dimensional molecular structure J. Med. Chem. 43 2000 2204 2216
34. a prediction method using grid molecular interaction fields J. Chem. Inf. Model. 47 2007 2172 2181
35. T.J. Yang Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism Drug Metab. Dispos. 27 1999 102 109
36. K.K. Nielsen The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways J. Pharmacol. Exp. Ther. 277 1996 1659 1664
37. J.G. Shin Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin Drug Metab. Dispos. 30 2002 1102 1107
38. L. Di Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS Int. J. Pharm. 335 2007 1 11
39. S. Wanchana QSAR analysis of the inhibition of recombinant CYP 3A4 activity by structurally diverse compounds using a genetic algorithm-combined partial least squares method Pharm. Res. 20 2003 1401 1408
40. D.F. Zullino, and Y. Khazaal Increased risk of gastrointestinal adverse effects under SSRI/NSAID combination may be due to pharmacokinetic interactions Br. J. Clin. Pharmacol. 59 2005 118 119
41. J.M. Hutzler Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: evidence for complex heme interactions Chem. Res. Toxicol. 19 2006 1650 1659
42. C.W. Yap, and Y.Z. Chen Prediction of cytochrome P450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines J. Chem. Inf. Model. 45 2005 982 992